Zogenix Inc Revenue Growth Rates (ZGNX), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Zogenix Inc   (NASDAQ: ZGNX)
 

ZGNX's Revenue Growth by Quarter and Year

Zogenix Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ZGNX Revenue (in millions $) FY 2021 FY 2020 FY 2019 FY 2018
4th Quarter December 26.61
3rd Quarter September 22.61
2nd Quarter June 18.79
1st Quarter March 13.68
FY 81.69

ZGNXs Annual Revenue
Zogenix Inc 's Revenue in the fiscal year 2021 $ 81.69 millions
Zogenix Inc 's Revenue in the fiscal year 2020 $ 13.64 millions
Zogenix Inc 's Revenue in the fiscal year 2019 $ 3.65 millions
Zogenix Inc 's Revenue in the fiscal year 2018 $ 7.17 millions
Zogenix Inc 's Revenue in the fiscal year 2017 $ 9.82 millions




ZGNX Revenue fourth quarter 2021 Y/Y Growth Comment
Zogenix Inc reported Revenue surge of 213.02% year on year in the fourth quarter 2021, to $ 26.61 millions, this is lower than Zogenix Inc 's recent average Revenue surge of 5.585519069102E+15%.

Looking into fourth quarter 2021 results within Major Pharmaceutical Preparations industry 18 other companies have achieved higher Revenue growth. While Zogenix Inc ' s Revenue doubling of 213.02% ranks overall at the positon no. 91 in the fourth quarter 2021.


ZGNX Revenue ( Y/Y Growth %) 2021
 2020 2019 2018
4th Quarter December 213.02 % 335.9 % - -
3rd Quarter September 690.56 % -4.98 % 41.31 % -
2nd Quarter June 1724.27 % -74.57 % 293.2 % -85.55 %
1st Quarter March 1155.05 % -65.51 % 280.72 % -69.26 %
FY   505.99 % 10.76 % 205.01 % -

Financial Statements
Zogenix Inc 's fourth quarter 2021 Revenue $ 26.61 millions ZGNX's Income Statement
Zogenix Inc 's fourth quarter 2020 Revenue $ 8.50 millions Quarterly ZGNX's Income Statement


ZGNX Revenue (Quarter on Quarter Growth %)

 2021
 2020 2019 2018
4th Quarter December 17.68 % 197.2 % -35.22 % -
3rd Quarter September 20.33 % 177.67 % -25.68 % 106.8 %
2nd Quarter June 37.35 % -5.5 % 28.16 % 24.1 %
1st Quarter March 60.94 % -44.1 % - -
FY (Year on Year)   505.99 % 10.76 % 205.01 % -


Back to ZGNX Growth rate Comparisons >> Back to ZGNX Growth rate Comparisons >>


Revenue fourth quarter 2021 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #19
Healthcare Sector #32
Overall #91

Revenue Y/Y Growth Statistics
High Average Low
1.0E+17 % 5.585519069102E+15 % -100 %
  (Dec 31 2017)
Revenue fourth quarter 2021 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #19
Healthcare Sector #32
Overall #91
Revenue Y/Y Growth Statistics
High Average Low
1.0E+17 % 5.585519069102E+15 % -100 %
  (Dec 31 2017)

Revenue by Quarter for the Fiscal Years 2018, 2019, 2020, 2021

Zogenix Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
4.6893731119994E+16 % 1.3792273858822E+15 % -100 %
(Mar 31 2018)  


ZGNX's IV. Quarter Q/Q Revenue Comment
Zogenix Inc achieved in the IV. Quarter 2021 below company average Revenue jump of 17.68% quarter on quarter, to $ 26.61 millions.

Within Major Pharmaceutical Preparations industry 99 other companies have achieved higher Revenue quarter on quarter growth. While Zogenix Inc 's Revenue growth quarter on quarter, overall rank is 889.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #100
Healthcare Sector #194
Overall #889
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #100
Healthcare Sector #194
Overall #889
Revenue Q/Q Growth Statistics
High Average Low
4.6893731119994E+16 % 1.3792273858822E+15 % -100 %
(Mar 31 2018)  


ZGNX's IV. Quarter Q/Q Revenue Comment
Zogenix Inc achieved in the IV. Quarter 2021 below company average Revenue jump of 17.68% quarter on quarter, to $ 26.61 millions.

Within Major Pharmaceutical Preparations industry 99 other companies have achieved higher Revenue quarter on quarter growth. While Zogenix Inc 's Revenue growth quarter on quarter, overall rank is 889.


Zogenix Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Dec 31 2021)		 12 Months Ending
(Sep 30 2021)		 12 Months Ending
(Jun 30 2021)		 12 Months Ending
(Mar 31 2021)		 12 Months Ending
(Dec 31 2020)
Cumulative Revenue 12 Months Ending $ 81.69 $ 63.59 $ 43.84 $ 26.08 $ 13.48
Y / Y Revenue Growth (TTM) 505.92 % 817.66 % 519.05 % 158.17 % 10.79 %
Year on Year Revenue Growth Overall Ranking # 101 # 0 # 25 # 30 # 162
Seqeuential Revenue Change (TTM) 28.47 % 45.06 % 68.09 % 93.43 % 94.57 %
Seq. Revenue Growth (TTM) Overall Ranking # 390 # 52 # 33 # 67 # 0


Cumulative Revenue growth Comment
Assuming the Zogenix Inc 's fiscal year would have ended in Dec 31 2021, Zogenix Inc would have reprted above average annual Revenue surge of 505.92% year on year, of $ 82 millions.
This marks a slow-down of the companys growth trends and from the 817.66% surge in Sep 30 2021.

In the Healthcare sector 35 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 101.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 50
Healthcare Sector # 36
Overall # 101

Revenue TTM Y/Y Growth Statistics
High Average Low
2201.58 %
 108.7 %
-111.89 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 50
Sector # 107
S&P 500 # 390
Cumulative Revenue growth Comment
Assuming the Zogenix Inc 's fiscal year would have ended in Dec 31 2021, Zogenix Inc would have reprted above average annual Revenue surge of 505.92% year on year, of $ 82 millions.
This marks a slow-down of the companys growth trends and from the 817.66% surge in Sep 30 2021.

In the Healthcare sector 35 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 101.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 50
Healthcare Sector # 36
Overall # 101

Revenue TTM Y/Y Growth Statistics
High Average Low
2201.58 %
108.7 %
-111.89 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 50
Sector # 107
S&P 500 # 390




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
ZGNX's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue surge for the quarter ending Dec 31 2021 within Healthcare SectorY/Y Change %Revenue for the quarter ending Dec 31 2021
Inotiv Inc 370.85%$ 370.847 millions
Codiak Biosciences Inc 369.33%$ 369.329 millions
Aerie Pharmaceuticals Inc 364.55%$ 364.555 millions
Insight Molecular Diagnostics Inc 357.97%$ 357.968 millions
Palvella Therapeutics Inc 349.81%$ 349.814 millions
Liquidia Corporation334.68%$ 334.679 millions
Astrotech Corp331.54%$ 331.538 millions
Voyager Therapeutics Inc 329.48%$ 329.478 millions
Roivant Sciences Ltd 323.32%$ 323.322 millions
Arvinas Inc 316.91%$ 316.907 millions
Delcath Systems Inc 315.98%$ 315.976 millions
Cyclo Therapeutics Inc 301.90%$ 301.903 millions
Cyclerion Therapeutics Inc 300.00%$ 300.000 millions
Pfizer Inc297.43%$ 297.427 millions
Viridian Therapeutics Inc 296.30%$ 296.296 millions
Creative Medical Technology Holdings Inc 287.17%$ 287.166 millions
Fresh Tracks Therapeutics Inc 285.19%$ 285.185 millions
Cidara Therapeutics Inc 283.51%$ 283.508 millions
Nabriva Therapeutics Plc276.46%$ 276.463 millions
Ginkgo Bioworks Holdings Inc 272.86%$ 272.862 millions
Seelos Therapeutics inc 271.43%$ 271.429 millions
Shockwave Medical Inc 270.59%$ 270.589 millions
Xencor Inc267.98%$ 267.984 millions
Karyopharm Therapeutics Inc 259.74%$ 259.741 millions
Humanigen Inc232.37%$ 232.372 millions
Lineage Cell Therapeutics Inc 229.01%$ 229.014 millions
Prothena Corporation Public Limited Company225.56%$ 225.556 millions
Zogenix Inc 212.95%$ 212.950 millions
Strata Critical Medical Inc 208.26%$ 208.264 millions
Blueprint Medicines Corporation206.72%$ 206.720 millions


About Zogenix Inc Revenue Growth Rates (ZGNX), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Zogenix Inc (CIK 1375151).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001193125-22-066856
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Zogenix Inc ’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.